Zentiva
Kenneth Lynard is a seasoned executive with extensive experience in finance and strategic leadership across the pharmaceutical and healthcare sectors. Currently serving as Board Member and Group CFO at Zentiva since 2019, Kenneth plays a pivotal role in driving transformation and growth for the pan-European generics and specialty pharmaceutical company. Prior to this, Kenneth was Managing Director and Group CFO at Affidea, overseeing accelerated growth and cost optimization for a leading medical services operator. Kenneth has also held senior positions at Gilead Sciences, where contributions included managing global operations and developing high-performing teams, as well as serving in various finance roles at companies such as Medtronic and Danske Bank. Kenneth holds an Executive MBA from IMD and a Master of Science in Business Economics & Auditing from Copenhagen Business School.
This person is not in any offices
Zentiva
5 followers
Zentiva is a Pan-European Platform developing, manufacturing and providing high-quality and affordable medicines to more than 100 million people in Europe. Zentiva has 4 wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. We offer solutions in key therapeutical areas like Cardiology & Circulation, Diabetes, Oncology, Respiratory, CNS and focus on expanding our portfolio in self-care. The company is Private Equity owned, delivering sustainable double-digit growth, with an ambitious 5-year plan for further strong (organic and inorganic) growth across Europe. We are a team of almost 5,000 unique talents bonded together by our mission to deliver high-quality and affordable medicines to people who depend on them every day. We want Zentiva to be a great place to work, where everyone feels welcomed and appreciated and can be their true selves contributing to the best of their ability.